Tuesday, September 25, 2018
Coherus Biosciences receives European Commission approval for UDENYCA
Coherus BioSciences announced the European Commission has granted marketing authorization to UDENYCA, a pegfilgrastim biosimilar. UDENYCA is one of the first pegfilgrastim biosimilars to gain marketing authorization in Europe. UDENYCA is currently under evaluation by the U.S. Federal Drug Administration with an action date of November 3, 2018.
https://thefly.com/landingPageNews.php?id=2795347
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.